Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With delisting from Toronto stock exchange I think someone wanted to get in cheap.
Next earnings will be 10K around 15 Jan. 2020
CleanSpark (CLSK) Announces Exclusive Contract For Energy Software Solutions With International Land Alliance (ILAL)
https://finance.yahoo.com/news/cleanspark-clsk-announces-exclusive-contract-140000547.html
CleanSpark Awarded $627,000 Software Controls and Energy Storage Contract
https://finance.yahoo.com/news/cleanspark-awarded-627-000-software-130005869.html
INNV: Innovus Pharmaceuticals, Inc. SEC Filing - Securities Registration Statement (S-1/A) February 8, 2019
https://seekingalpha.com/filing/4338078
Dr. Damage strikes again.
More dilution.
Next earnings release should be interesting. Should be around March 7, 2019
$32 price target on Opiant's shares.
VALUE IN OPIANT AFTER ADAPT DEAL: In a research note to investors, Cantor Fitzgerald's Folkes argued that Emergent BioSolutions' acquisition of Adapt Pharma underscores the value of the opioid overdose market. At a market cap of about $44M, the analyst pointed out he believes Opiant presents an attractive risk/reward, even if it captures only a portion of the growing market. Opiant is expected to generate about $30M-38M in cash from Narcan royalties and the milestone payment in 2019, to fund the development of its own opioid overdose nasal spray, OPNT003, and the other programs in the company's pipeline, he noted. Overall, Folkes said he expects investors to begin to appreciate the market potential of Opiant's pipeline, which should drive the stock higher. The analyst reiterated an Overweight rating and $32 price target on Opiant's shares.
Read more at:
https://thefly.com/landingPageNews.php?id=2783481
https://thefly.com/landingPageNews.php?id=2783481&headline=OPNT;EBS-Opiant-jumps-as-analyst-sees-value-after-opioid-overdose-spray-maker-bought
Citron Still Short Tilray, Notes Canopy Growth Is The 'Global Leader' In Cannabis
https://finance.yahoo.com/news/citron-still-short-tilray-notes-193604720.html
How low can this go? Waiting for this to hit bottom before buying.
Based on gross revenues of approximately $250 million in 2019, we estimate that Opiant would receive approximately $34.3 million in royalty and milestone payments (and result in net revenues to Emergent of approximately $215 million). This assumes that sales of NARCAN® Nasal Spray do not exceed $200 million in 2018, as Opiant is owed a $15 million milestone at that threshold.
https://finance.yahoo.com/news/opnt-adapt-pharma-acquired-650-190000844.html
OPNT: Developing Longer-Acting Opioid Overdose Treatment
https://finance.yahoo.com/news/opnt-developing-longer-acting-opioid-170000858.html
"Based on these adjustments we have raised our valuation from $51 to $55."
This stock shot up $6 at 1140am and I could find no news. Anyone?
On February 8, 2018, Opiant Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing that it will record a total of approximately $11.7 million in royalty and milestone payments for the five-month period ended December 31, 2017 related to full-year 2017 sales of NARCAN® Nasal Spray (“NARCAN”) for opioid overdose by the Company’s commercial partner, Adapt Pharma Operations Limited (“Adapt Pharma”). Going forward, the Company will receive 90% of royalty and milestone payments related to NARCAN sales directly from Adapt Pharma, with its royalty and milestone payment obligations to SWK Funding LLC (“SWK”) being correspondingly reduced to 10%, as SWK has been paid $26.25 million per the terms of that certain Purchase and Sale Agreement, dated as of December 13, 2016, by and between the Company and SWK.
OPNT will receive 90% of royalty and milestone payments related to NARCAN sales directly from Adapt Pharma.
$$$$$
From the 10k:
"NOTE 1 – ORGANIZATION, BASIS OF PRESENTATION AND NATURE OF OPERATIONS
Organization
MyECheck, Inc. (“MEC”) (“the Company”) was incorporated in the state of Delaware on October 29, 2004. The Company’s office is located at Folsom, California. On May 25, 2012 the Company was redomiciled in the State of Wyoming. In addition, the Company registered as a foreign corporation in the State of California on October 16, 2014.
GreenPay, LLC (“GreenPay”), a wholly owned subsidiary of the Company, incorporated in the State of Wyoming on March 11, 2014 was acquired by MyEcheck on August 20, 2014. After the acquisition, GreenPay registered as a foreign limited liability company in the State of California on November 10, 2014."
The copyright on the website is 2017 so that is encouraging.
Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid Overdose
GlobeNewswire•December 20, 2017
Opiant Expects to Receive 90% of NARCAN Sales-Related Royalty and Milestone Payments, Going Forward
SANTA MONICA, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it expects that, beginning in the first quarter of 2018, it will receive 90% of royalty and milestone payments related to NARCAN sales directly from Adapt Pharma. Correspondingly, the royalty and milestone payments due to SWK Holdings will now be reduced to 10%, as they will have been paid the $26.25 million per the royalty monetization agreement between Opiant and SWK.
MEET showed us the beef today regarding revenues and EBITDA! Up we go! $$$$
On November 28, 2017, Savara Inc. (“Savara”) entered into Amendment No. 1, effective September 30, 2017, to the Research Program Award Letter Agreement between Savara and Cystic Fibrosis Foundation Therapeutics, Inc. (“CFFT”) dated September 30, 2013 (as amended, the “Award Agreement”), pursuant to which the amount of the development award available to Savara was increased by $5,000,000 to an aggregate of $6,700,000. CFFT is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, and the award is available to support the continued development of Savara’s AeroVanc program. The award can be drawn down by Savara as needed upon the achievement of certain milestones set forth in the Award Agreement.
EPS -$2.77 just posted for latest quarter.
Price/book ratio is a rediculous .02.
This stock is worth 10 to 100X current price.
BREAKING OUT ON A ONE YEAR HIGH!!!
PTN breaking out?
BARCHART.COM 100% BUY
Resistance at $11.05
"Meet Group posted a healthy 88% year-over-year growth in total revenue, up to $32.2 million, with mobile revenue up 47% to $23.7 million. Adjusted net income checked in at $0.11 per share, up from the prior year's $0.10 per share."
AUBURN HILLS, Mich. (AP) _ Unique Fabricating Inc. (UFAB) on Thursday reported third-quarter net income of $715,000.
On a per-share basis, the Auburn Hills, Michigan-based company said it had profit of 7 cents. Earnings, adjusted for one-time gains and costs, were 10 cents per share.
The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 15 cents per share.
The foam and rubber products maker posted revenue of $41.2 million in the period, which also fell short of Street forecasts. Three analysts surveyed by Zacks expected $42.7 million.
Unique Fabricating expects full-year earnings in the range of 64 cents to 68 cents per share, with revenue in the range of $173 million to $177 million.
The Meet Group Announces Closing of Lovoo Acquisition
[Business Wire]
Business WireOctober 19, 2017
The Meet Group Announces Closing of Lovoo Acquisition
The Meet Group Announces Closing of Lovoo Acquisition Multimedia Gallery URL
NEW HOPE, Pa.--(BUSINESS WIRE)--
The Meet Group, Inc. (MEET), a public market leader in the mobile meeting space, has completed its acquisition of Lovoo GmbH. The LOVOO app is the most downloaded dating app in Germany, Switzerland, and Austria combined.
Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc
[Marketwired]
MarketwiredSeptember 26, 2017
AUSTIN, TX --(Marketwired - September 26, 2017) - Savara, Inc. (SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the initiation of the AVAIL study, a Phase III, randomized, double-blind, placebo-controlled study of AeroVanc (vancomycin hydrochloride inhalation powder) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF).
Savara Reports Completion of Enrollment in Phase 2 Clinical Trial of Aironite for the Treatment of HFpEF
October 18, 2017) - Savara, Inc. (SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today reported that patient enrollment is now complete in a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial of Aironite, a sodium nitrite solution for inhalation via nebulization, in patients with heart failure with preserved ejection fraction (HFpEF). The 100-patient study, known as the Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (INDIE-HFpEF) study, is sponsored by Duke Clinical Research Institute (DCRI) as the Coordinating Center for the Heart Failure Clinical Research Network (HFN) and is being conducted at various clinical centers that are part of the HFN. Savara expects that top-line results from the INDIE-HFpEF study will be available in the first half of 2018.
Opiant Pharmaceuticals Files $150 Mln Shelf for Stock and Warrants 10/16/2017 16:15 PM EDT
04:15 PM EDT, 10/16/2017 (MT Newswires) -- Opiant Pharmaceuticals (OPNT) filed to sell up to $150 million in stock and warrants.
$2/SH book value for BAA! What's not to like?
CTMX $41 price target
PTN $3.75 average price target!
Up 35% after hours!
Under the terms of the agreement, Amgen and CytomX will co-develop a Probody T-cell engaging bispecific against EGFRxCD3 with CytomX leading early development. Amgen will lead later development and commercialization with global late-stage development costs shared between the two companies. Amgen will make an upfront payment of $40 million and purchase $20 million of CytomX common stock. CytomX will be eligible to receive up to $455 million in development, regulatory and commercial milestones for the EGFR program. Amgen will lead global commercial activities with CytomX able to opt into a profit share in the U.S. and receive tiered, double-digit royalties on net product sales outside of the U.S.
Canaccord target price is $6!
UFAB yield on dividend 7.89%
UFAB PE = 9.42
Enough cash in the bank until 2020 as stated in their quarterly. And lots of product in the R&D pipeline.
$200 million in the bank. No cash raises needed for a long time.